SCHEDULE 13G/A: Cormorant Asset Management Reports 0% Beneficial Ownership in VYNE Therapeutics Due to Warrant Exercise Limitations

Cormorant Asset Management, LP and Bihua Chen have filed an amended Schedule 13G, reporting 0% beneficial ownership of VYNE Therapeutics Inc. common stock, despite holding warrants exercisable for over 3 million shares, due to a contractual 9.99% exercise limitation.

Summary

• Cormorant Asset Management, LP and Bihua Chen, collectively referred to as the "Reporting Persons," have filed an Amendment No. 1 to Schedule 13G regarding their holdings in VYNE Therapeutics Inc.
• As of March 31, 2025, the Reporting Persons report an aggregate beneficial ownership of 0.00 shares, representing 0% of VYNE Therapeutics Inc.'s common stock.
• This 0% beneficial ownership is due to a contractual limitation on the exercise of pre-funded warrants (the "Warrants") held by the Reporting Persons.
• The Warrants are exercisable for up to 3,060,143 shares of Common Stock.
• The exercise limitation prevents the holders from beneficially owning in excess of 9.99% of the Issuer's outstanding common stock upon exercise.
• The filing explicitly states that if not for this exercise limitation, the Reporting Persons would beneficially own in excess of 9.99% of the Issuer's Common Stock.
• The percentage of class is calculated based on 16,664,892 shares of Common Stock outstanding as of May 1, 2025, as reported in the Issuer's Form 10-Q filed on May 8, 2025.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual, technical disclosure of ownership status, not a performance report. The 0% beneficial ownership is explained by a contractual limitation on warrants, indicating a neutral impact on sentiment as it's not a true divestment.

Positives

• Cormorant Asset Management, a notable investment firm, holds pre-funded warrants exercisable for a substantial number of shares (3,060,143) in VYNE Therapeutics, indicating a significant prior investment interest.
• The filing clarifies that the 0% beneficial ownership is due to a contractual limitation (9.99% cap on warrant exercise) rather than a complete divestment, suggesting continued underlying interest.

Negatives

• The reported 0% beneficial ownership, while explained by warrant limitations, could be misinterpreted as a complete lack of ownership or a divestment if the context is not fully understood.

Risks

• Misinterpretation of the 0% beneficial ownership figure by investors who may not fully understand the implications of the warrant exercise limitation, potentially leading to incorrect assumptions about institutional interest.

Future Outlook

The document indicates that the Reporting Persons hold pre-funded warrants that, if not for a contractual exercise limitation, would result in beneficial ownership exceeding 9.99% of the Issuer's Common Stock. This suggests a potential for increased ownership should the exercise limitation be removed or adjusted in the future.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11." (Certification by Bihua Chen, Managing Member of Cormorant Asset Management, LP and Bihua Chen individually)

Industry Context

This filing is a routine disclosure of institutional ownership status for a biotechnology or pharmaceutical company (VYNE Therapeutics Inc.). It reflects a specific investor's position and does not provide broader insights into industry trends or competitive landscape, beyond indicating continued institutional interest in the sector.

Stakeholder Impact

• Shareholders: Provides updated information on institutional ownership, clarifying that Cormorant Asset Management's beneficial ownership is technically 0% due to warrant exercise limitations, but they still hold significant warrants.

Key Dates

Keywords

VYNE Therapeutics Inc., Cormorant Asset Management, Schedule 13G/A, Beneficial Ownership, Pre-funded Warrants, Common Stock, SEC Filing, Institutional Investor, Ownership Disclosure